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Introduction
Neurodevelopmental disorders, including intellectual
disability (ID) and autism, have a strong genetic compo-
nent, but only a few of the underlying genes have been
identified. Candidate-gene discovery has accelerated in
recent years by the implementation of high-resolution
genomic arrays. However, detected copy-number variants
(CNVs) often either encompass multiple genes or are too
rare to provide causal evidence for a particular candidate
transcript. Autism susceptibility candidate 2 (AUTS2),
located on 7q11.22 (MIM 607270), represents such an ID
candidate with inconclusive evidence for causality.
AUTS2 was first identified as a candidate for neurocogni-
tive defects because a translocation-breakpoint analysis in
twins with autism, developmental delay, and epilepsy
showed that one of the breakpoints disrupted AUTS2.1
Besides the twins, seven additional cases have now been re-
ported to have a disrupted AUTS2 coding region: four indi-
viduals with a translocation breakpoint,2,3 one with an
inversion breakpoint disrupting AUTS2,2–4 and two with
intragenic deletions.2,5 These individuals manifested ID
and developmental delay (all nine), dysmorphic features
(six), autism (four), and skeletal abnormalities (three).
This overview does not include persons with intronic dele-
tions in AUTS2 because the functional significance of such
intronic variation is unclear.6
Complicating the candidacy of this locus, some of the
genomic rearrangements affecting AUTS2 disrupt other
genes as well. A combination of cytogenetic and
sequencing studies suggested that CNTNAP2 (7q35) might
be causal in an individual with a 7q inversion disrupting
AUTS2 and CNTNAP2 (MIM 604569);4 likewise, for three
larger multigenic de novo deletions (in the DECIPHER
database) encompassing AUTS2, it is unclear whether the
disruption of AUTS2 alone drives the phenotype.7 The
data presented by Nagamani et al.5 on two individuals
with intragenic deletions suggest that deletions in AUTS2
alone might be pathogenic. However, the number of
affected individuals was too small to exclude the role of
other genes or to delineate a phenotype.5 Here, we present
direct evidence from both clinical and genetic data and
animal studies for the causal relation of AUTS2 with an
ID syndrome and delineate the associated phenotype.
Furthermore, we provide evidence that functional
elements in the C terminus of AUTS2 are major contribu-
tors to both the neurodevelopmental and craniofacial
phenotypes of individuals with C-terminal deletions or re-
arrangements at this locus.Subjects and Methods
Subjects
Routine diagnostic array comparative genomic hybridization
(CGH) was performed for ID and/ormultiple congenital anomalies
(MCAs) for a total of 49,684 individuals across ten diagnosticThe Americcenters in The Netherlands, Belgium, Great Britain, the United
States, and Canada (each center used their standard diagnostic
platform; in total, six analogous platforms were used). In some
of these individuals, karyotyping was also performed. From this
cohort, we selected all individuals with a deletion involving
AUTS2, as well as one person with a translocation and another
person with an inversion in which one of the breakpoints was
in AUTS2. To map the region further and to delineate the associ-
ated phenotypes, we obtained peripheral-blood samples and
collected clinical information through either medical letters or
a data sheet filled in by the referring physicians with approval of
the local medical ethical committee. Results were confirmed
with different methods (high-density array, multiplex ligation-
dependent probe amplification [MLPA], and fluorescence in situ
hybridization [FISH]) depending on the laboratory (see Tables S1,
S2, and S3, available online). Exact breakpoint delineation of the
translocation with one breakpoint in 7q11.22 was performed
with FISH, and the inversion was characterized with whole-
genome sequencing, as previously described.8–10 Informed
consent was obtained from parents or caregivers as appropriate,
and specific consent for publishing photographs was obtained
from all individuals whose photographs are shown here. Institu-
tional approval of the local medical ethical committee was ob-
tained as well. Individuals with a confirmed exonic deletion or
a genomic rearrangement involving AUTS2 and available clinical
data were included for phenotypic studies.Controls
To assess the frequency of AUTS2 deletions within a large general
population, we analyzed CNV data of 16,784 subjects from several
control groups. A total of 4,783 DNA samples from the Wellcome
Trust Case Control Consortium 2 (WTCCC2) were analyzed with
a SNP array. This control group included individuals who had
been nationally ascertained and regarded as healthy from the
1958 Birth Cohort and the UK Blood Service collection (October
26, 2011).11 Further control CNV data from 8,329 cell-line- and
blood-derived controls were obtained primarily from genome-
wide association studies of nonneurological phenotypes. Because
these included 2,090 controls from the UK Blood Service collec-
tion, this set added only 6,239 unique controls. Although these
data were not ascertained specifically for neurological disorders,
they consist of adult individuals who provided informed consent
as described previously.12 In addition, publicly available data from
HapMap phase 3 (October 26, 2011), which consists of 1,056
healthy controls from 11 different populations, were checked for
deletions involving AUTS2.13 CNV data were available from the
following four control sets: The Ottawa Heart Institute (OHI)
controls (n ¼ 1,234) from Canada, POPGEN controls (n ¼ 1,123)
from Germany, SAGE controls (n ¼ 1,287) from the United States,
and the Low-Lands-Consortium controls (n ¼ 981) from The
Netherlands.13–15 See Table S4 for details on all cohorts and the
array platforms used. The array platforms used for controls have
the same or a comparable resolution as the platforms used for
cases. The number of deletions found in the cases was compared
to that in the controls with a Fisher’s exact test.Genotype-Phenotype Correlations
We received clinical data from 17 individuals and 4 family
members carrying an exonic AUTS2 disruption. We used these
individuals to identify features that occurred in at least two unre-
lated individuals, i.e., features with a minimal frequency of 10%.an Journal of Human Genetics 92, 210–220, February 7, 2013 211
A recent systematic review of Oeseburg et al.16 showed that in
a general ID cohort, the most frequent additional health condi-
tions (epilepsy and cerebral palsy) are as frequent as 20%, but
the remainder of the comorbid clinical features (including autism
and a congenital malformation in general) are seen in less than
10%.16 Therefore, a frequency of 10% for a specific feature in
this AUTS2 cohort is an enrichment compared to ID cases in
general. These recurrent features were scored for all individuals
and family members carrying the familial deletion, and asymmet-
rically occurring features were counted as positive. The sum of
positive features was counted for each individual and was defined
as his or her individual AUTS2 syndrome severity score.
Becausedeletionsorgenomic rearrangements affecting the30 end
of the AUTS2 coding sequence seem to be associated with a more
severe phenotype, persons with exonic deletions were categorized
in two groups depending on whether the deletion disrupted the
highly conserved AUTS2 segment (containing exons 9–19) that is
also encoded by the alternative 30 transcript (see Alternative Tran-
scription Start Sites below and the Results). We used a Kolmo-
gorov-Smirnov test to test whether the corresponding AUTS2
syndrome severity scores for these twogroups differed significantly.Alternative Transcription Start Sites
To search for an explanation for the observed genotype-pheno-
type trend, we first determined the evolutionary conservation of
human AUTS2 exonic sequences. We used the following species
for comparison: gorilla (Gorilla gorilla; gorGor3), macaque (Macaca
mulatta; Mmul_1), dog (Canis familiaris; Broadd2), cow (Bos taurus;
Btau_4.0), pig (Sus scrofa; Sscrofa9), mouse (Mus musculus;
NCBIM37), chicken (Gallus gallus; Washuc2), clawed frog (Xenopus
tropicalis; JGI_4.2), and zebrafish (Danio rerio; Zf9). Accession
numbers of protein sequences are ENSGGOP00000011519,
ENSMMUP00000023254, ENSBTAP00000002697, ENSSSCP0000
0008253, ENSCAFP00000016549, ENSMUSP00000062515, ENSG
ALP00000001729, ENSXETP00000007747, and ENSDARP00000
073379. Two different methods were used. We first aligned the
predicted protein of the longest isoform in humans to the pre-
dicted amino acid sequences of the orthologous species by using
MUSCLE v.3.8 software.17 For that purpose, we downloaded
sequences from the latest builds from Ensembl. Then, to detect
similarity in nonannotated or noncoding genomic DNA, we
used the tblastn algorithm (see Web Resources) with the human
amino acid sequence as query.18 The degree of homology was
calculated as the percentage of identical amino acids.
Second, we searched for putative alternative transcription start
sites (TSSs) that were associated with a shorter 30 isoform in the
human brain. We used mRNA from the caudate nucleus and the
medial frontal gyrus from one donor provided by the Dutch Brain
Bank and performed a replication experiment by the same proce-
dure on a mRNA sample from the medial frontal gyrus of a second
donor. Rapid amplification of 50 cDNA ends (50 RACE) was per-
formed with the Ambion FirstChoice RLM-RACE kit according to
the manufacturer’s instructions. Nested PCR amplification was
performed with 50-ATGTCTTCGGCTGAAATGCT-30 as the outer
AUTS2-specific reverse primer and 50-GGAAGAGACTGTGCCGG
TAG-30 as the inner primer (Figures S1A and S1B).Knockdown and Rescue Experiments in Zebrafish
Embryos
To investigate the role of AUTS2 in the regulation of head size,
neuronal development, andmorphology in general, we performed212 The American Journal of Human Genetics 92, 210–220, Februaryzebrafish knockdown experiments. Zebrafish (Danio rerio) embryos
were raised andmaintained as described.19 Splice-blocker morpho-
linos (MOs) against the AUTS2 ortholog auts2 were designed and
obtained from Gene Tools (Table S5). We injected 1 nl of diluted
MOs (4.5 ng for the 50 MO targeting the exon 2 donor splice and
6 ng for the 30 MO targeting the exon 10 donor splice) and/or
100 pg of mRNA into wild-type zebrafish embryos at the 1- to
2-cell stage (n ¼ 50–100 embryos per injection dose) and per-
formed RT-PCR to measure efficiency of the splice blocking. In-
jected embryos were scored visually at 3 days postfertilization
(dpf) and classified as normal or microcephalic on the basis of
the relative head size compared with that of age-matched controls
from the same clutch. For rescue experiments, the human wild-
type mRNAs (full-length or short transcript [GenBank accession
numbers JQ670866 and JQ670867, respectively]) were cloned
into the pCS2 vector and transcribed in vitro with the SP6Message
Machine kit (Ambion); 100 pg of the human wild-type mRNAs
were coinjected with the MOs. All experiments were repeated
three times and evaluated statistically with a Student’s t test.
Alcian-blue staining of cartilaginous structures was performed
for investigating the morphology of the head. Zebrafish embryos
were fixed with 4% paraformaldehyde (PFA), and the cartilage
structures were visualized by Alcian-blue staining according to
an established protocol.20 Further, whole-mount immunostain-
ings with either HuC/D (postmitotic neurons) or phosphohistone
H3 (proliferating cells) were performed for investigating neuronal
development and head-size regulation at a cellular level. Embryos
were fixed in 4% PFA overnight and stored in 100% methanol at
20C. After rehydration in PBS, PFA-fixed embryos were washed
in immunofluorescence (IF) buffer (0.1% Tween-20 and 1% BSA in
PBS 13) for 10 min at room temperature. The embryos were incu-
bated in the blocking buffer (10% FBS and 1% BSA in PBS 13) for
1 hr at room temperature. After two washes in IF buffer for 10 min
each, embryos were incubated in the first antibody solution, 1:750
anti-histone H3 (ser10)-R (sc-8656-R, Santa Cruz) or 1:1,000 anti-
HuC/D (A21271, Invitrogen), in blocking solution overnight at
4C. After two washes in IF buffer for 10 min each, embryos
were incubated in the secondary antibody solution, 1:1,000 Alexa
Fluor donkey anti-rabbit IgG and Alexa Fluor goat anti-mouse IgG
(A21207, A11001, Invitrogen), in blocking solution for 1 hr at
room temperature. Staining was quantified by the counting of
positive cells in defined regions of the head and with ImageJ
software.Results
Genotypes
To assess the candidacy of AUTS2 in cognitive impairment
in humans, we examined the AUTS2 region in 49,684 indi-
viduals with ID and/or MCAs by using array CGH and/or
karyotyping. We identified 44 deletions encompassing at
least part of AUTS2 and a maximum of two other genes
(WBSCR17 and CALN1 [MIM 607176]), and conventional
karyotyping revealed one translocation and one inversion
each with one breakpoint in AUTS2 (Table S1). AUTS2-en-
compassing duplications found in this cohort were not
included in this study because the functional relevance
of these lesions is unclear. Twenty-four deletions were
found to include at least one AUTS2 exon, whereas another
17 did not. For the remaining three deletions, it was7, 2013
Figure 1. Overview of AUTS2 Aberrations in the Probands
The location of the deletions is indicated by the red bars, the inversion breakpoint is indicated by an arrowhead, and the translocation
breakpoint area is indicated by the red horizontal bracket. CNVs extracted from the Database of Genomic Variants are in purple (CNVs
found in bacterial-artificial-chromosome studies are not included). The AUTS2 syndrome severity score of the probands is shown on the
right. Darker shades indicate a more severe and/or more specific phenotype. Color coding of AUTS2 syndrome severity scores is as
follows: white, <7; light gray, 7–12; gray, 13–18; and dark gray, >18. See also Figure S2 and Table S7.unclear whether they included an exon because of the
limited resolution of the array. For these three individuals,
we had no consent to perform further studies.
Overall, in our cohort of 49,684 affected individuals, we
identified 24 persons (0.05%) harboring deletions disrupt-
ing the coding sequence. To assess the significance of this
observation, we analyzed 16,784 controls from 12 cohorts
by using arrays with high-density coverage of the AUTS2
locus (Table S4). Although nine deletions were found,
none of them disrupted an AUTS2 exon (Table S6). The
difference between exonic deletions in the cases (24/
49,651) and those in controls (0/16,784) was highly signif-
icant (p ¼ 0.00092), suggesting that exonic disruptions of
AUTS2 give rise to a highly penetrant phenotype in hu-
mans. This is supported by CNV data from the latest
version of the Database of Genomic Variants (August 25,
2012), wherein none of the array-based studies show
CNVs that disrupt an exon, and by the fact that none of
the 24 probands with an exonic AUTS2 deletion had
a rare de novo CNV at another locus (Table S1).
We were able to obtain phenotypic data from 15 out of
24 probands with an exonic AUTS2 deletion (cases 1–15),
from the inversion case (16) and the translocation case
(17) with one breakpoint in AUTS2, as well as from four
family members carrying the familial AUTS2 deletion. In
these 17 probands, MLPA, FISH, high-density array CGH,
and breakpoint sequencing confirmed the aberrations
and further delineated the breakpoints. (Figure 1 and
Table S1).The AmericIn total, 21 individuals from 17 families were included in
our genotype-phenotype study (Table S7). In 8 (cases 5, 8,
10, 12, 14, 15, 16, and 17) out of 11 probands in which
both parents were available for genetic testing, the
AUTS2 aberrations occurred de novo; the other three
probands inherited the AUTS2 deletion from an unaffected
parent (case 1) or an affected parent (cases 4 and 6). In six
probands (cases 2, 3, 7, 9, 11, and 13), the inheritance
status of the AUTS2 deletion could not be fully resolved
because one or both parents were unavailable for testing.
Of the ten individuals with an intragenic deletion (not
including the first and last exon), four probands (cases 6,
7, 8, and 11) carried a deletion predicted to cause a frame-
shift, whereas the other six individuals (cases 1, 2, 3, 4, 9,
and 10) carried in-frame deletions. Finally, in case 14, the
deletion also included one downstream gene (WBSCR17),
and in cases 13 and 15, the deletions also affected two
downstream genes (WBSCR17 and CALN1) (Figure 1, Table
S7, and Figure S2).
Phenotypes
Next, we asked whether there were any recurrent pheno-
typic features associated with AUTS2 disruptions. All 17
probands from whom detailed clinical data were available
had ID and/or developmental delay; this had been the
reason for diagnostic testing. One of the parents (the
mother of case 4) carrying an AUTS2 deletion had learning
difficulties, one (the mother of case 6) had mild ID, and
one (the father of case 1) had normal intelligence. Sevenan Journal of Human Genetics 92, 210–220, February 7, 2013 213
Figure 2. Facial Characteristics of Cases with an AUTS2 Aberration
(A) Case 1 at age 3 years shows no dysmorphic features.
(B and L) Front (B) and side (L) views of case 4 at age 2.5 years show a repaired cleft lip, mild proptosis, and short and mild upslanting
palpebral fissures.
(C) The mother of case 4 shows a repaired cleft lip, ptosis, and retrognathia.
(D) Case 5 at age 3 years shows highly arched eyebrows, mild downslanting palpebral fissures, epicanthal folds, and a short philtrum.
(E, F, M, and N) Front (E) and side (M) views of case 6 at age 6 years. She is hyperteloric and has ptosis and downslanting palpebral
fissures, a short philtrum, and a narrow mouth similarly to her brother, shown in (F) and (N) at the age of 10 years.
(G and O) Front (G) and side (O) views of case 9 at age 32 years show hypertelorism, proptosis, upslanting palpebral fissures, a short
upturned philtrum, and a narrow mouth.
(H) Case 10 at age 2 years shows a prominent nasal tip, anteverted nares, and a short philtrum.
(I and P) Front (I) and side (P) views of case 13 at age 5.5 years show hypertelorism, ptosis, a broad nasal bridge, a short and upturned
philtrum, and a narrow mouth.
(J, K, andQ) Case 15 at age 1 year (J) and 4.8 years (K andQ) shows a broad nasal bridge, short palpebral fissures and a short philtrum, and
a narrow mouth. See also Table 1 and Table S7.probands (cases 2, 5, 9, 12, 13, 16, and 17) were diagnosed
with autism spectrum disorder or showed autistic behavior.
In addition to the expected neurocognitive defects, we also
observed a constellation of other recurrent clinical features
in individuals with exonic deletions. These included
microcephaly (14 individuals), short stature (12), feeding
difficulties (10), hypotonia (8), and cerebral palsy (9). We
also found recurrent dysmorphic features: hypertelorism
(10), proptosis (6), ptosis (8), short palpebral fissures (8),
epicanthal folds (7), a short and/or upturned philtrum
(8), micrognathia (7), and a narrow mouth (12). Less
frequent features were skeletal abnormalities including
(signs of) arthrogryposis (3), umbilical or inguinal hernia
(2), and heart defects (3) (Figure 2 and Table 1). The striking
phenotypic complexity and variable size and position of214 The American Journal of Human Genetics 92, 210–220, Februarythe CNVs prompted us to evaluate the clinical information
from the 17 probands and 4 family members carrying the
familial AUTS2 deletion included in this study to derive
pathology scores on the basis of simple, objective criteria;
we summarized these as the ‘‘AUTS2 syndrome severity
score’’ (the maximum score is 32). Even though this para-
digm is a crude approximation of the phenotypic diversity
at this locus, we nonetheless observed dichotomization of
phenotypes. Cases and family members 1–4, (all with 50 in-
frame deletions) scored significantly lower (median AUTS2
syndrome severity score ¼ 5) than did cases (5–17) and
family members with deletions of downstream exons,
whole-gene deletions, or exons 1–4 deletions including
the initiation codon (median AUTS2 syndrome severity
score ¼ 12) (Figures 1 and 3 and Table S7). This difference7, 2013
Table 1. Clinical Features Characterizing the Individuals with
AUTS2 Syndrome
Clinical Features
Cases
This Study
(n/total)
Published
(n/total)
General
Age at examination 11 months
to 32 years
3–16 years
Sex 13 female
and 8 male
5 female
and 4 male
De novo occurrence 9/13 (69%) 8/9 (89%)
Growth and Feeding
Low birth weight 7/17 (41%) 2/8 (25%)
Short staturea 12/20 (60%) 4/9 (44%)
Microcephalyb 14/20 (70%) 1/6 (17%)
Feeding difficulties 10/21 (48%) 4/5 (80%)
Neurodevelopmental Features
Intellectual disability and/or
development delay
20/21 (95%) 9/9 (100%)
Autism or autistic behavior 7/21 (33%) 4/6 (67%)
Sound sensitivity 2/8 (25%) 2/4 (50%)
Hyperactivity and/or ADHD 3/21 (14%) 1/4 (25%)
Neurological Disorders
Generalized hypotonia 8/21 (38%) 4/7 (57%)
Structural brain anomaly 3/11 (27%) 4/9 (44%)
Cerebral palsy and/or spasticity 9/21 (43%) 1/4 (25%)
Dysmorphic Features
Highly arched eyebrows 8/21 (38%) 1/5 (20%)
Hypertelorism 10/21 (48%) 0/5 (0%)
Proptosis 6/21 (29%) 2/5 (40%)
Short palpebral fissures 8/21 (38%) 2/5 (40%)
Upslanting palpebral fissures 4/21 (19%) 1/5 (20%)
Ptosis 8/21 (38%) 2/5 (40%)
Epicanthal fold 7/21 (33%) 1/5 (20%)
Strabismus 5/21 (24%) 3/6 (50%)
Prominent nasal tip 5/21 (24%) 2/5 (40%)
Anteverted nares 3/21 (14%) 2/5 (40%)
Deep and/or broad nasal bridge 7/21 (33%) 1/5 (20%)
Short and/or upturned philtrum 8/21 (38%) 5/7 (71%)
Micrognathia and retrognatia 7/20 (35%) 2/5 (40%)
Low-set ears 6/20 (30%) 2/5 (40%)
Ear pit 2/20 (10%) 0/5 (0%)
Narrow mouth 12/21 (57%) 3/5 (60%)
Table 1. Continued
Clinical Features
Cases
This Study
(n/total)
Published
(n/total)
Skeletal Abnormalities
Kyphosis and/or scoliosis 2/9 (22%) 3/5 (60%)
Arthrogryposis and/or shallow palmar
creases
3/20 (15%) 1/3 (33%)
Tight heel cords 5/8 (62%) 1/1 (100%)
Congenital Malformations
Hernia umbilicalis and/or inguinalis 2/21 (9%) 1/9 (11%)
Patent foramen ovale and/or atrial
septum defect
3/21 (14%) 1/9 (11%)
This table shows the frequency of clinical features in AUTS2 syndrome as the
number of affected individuals with this feature (n) in relation to the total
number of individuals for whom information was available for each feature
(total). For a more detailed overview, see Table S7, which also includes an over-
view of cases described in the literature.2–5
aShort stature is defined as height below the tenth percentile.
bMicrocephaly is defined as skull size below the second percentile.
The Americwas significant regardless of the inclusion or exclusion of
affected family members (p ¼ 0.001 or p ¼ 0.011, respec-
tively).
Detection of a C-Terminal AUTS2 Isoform
The apparent dependence of severity scores on CNV loca-
tion prompted us to evaluate the evolutionary conserva-
tion of each AUTS2 exon (Figures S3 and S4); conservation
was especially high in the 30 gene region. Given the fact
that the ENSEMBL annotation of the AUTS2 sequences
predicts the presence of several splice isoforms, we next
looked for the presence of alternative isoforms in human
brain mRNA. Using 50 RACE, we identified a short 30
AUTS2 mRNA variant starting in the middle of exon 9,
depicted in Figure 4. All transcripts detected employed
the same start site (see also Figures S1C and S1D). The
reading frame of the short transcript is identical to that
of the full-length AUTS2 transcript and is predicted to
encode a polypeptide of 697 amino acids instead of the
1,259 amino acids of the full-length protein. The evolu-
tionary conservation from humans to zebrafish suggests
an important biological function for AUTS2 and, together
with the shorter transcript, gave us the opportunity to
analyze the function of the C terminus of AUTS2 in a zebra-
fish model.
In Vivo Analysis of AUTS2 in Zebrafish Embryos
Taken together, our CNV mapping data, our RACE anal-
yses, and the strong correlation between phenotypic
severity and position of the deletion suggest that the 30
end of the AUTS2 locus contains major functional
elements that are encoded by both the full-length tran-
script and the shorter C-terminal isoform. Microcephaly
is one of the most consistent clinical features in our cases
(14/20; Table 1). We therefore asked whether AUTS2,an Journal of Human Genetics 92, 210–220, February 7, 2013 215
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Figure 3. Scatter Plot of the AUTS2 Syndrome Severity Score for
Disruptions Affecting the N or C Terminus of AUTS2
Scatter plot of the AUTS2 syndrome severity score for disruptions
that affect the highly conserved amino acid sequence block en-
coded by exons 9–19 (yes) and the deletions not affecting this
amino acid sequence (no) (see also Table S7 and Figure 4). The
numbers refer to case numbers. The following abbreviations are
used: f, father of patient x; m, mother of patient x; and s, sibling
of patient x (see Table S7). The AUTS2 syndrome severity scores
between these groups of cases differ significantly (p ¼ 0.001, Kol-
mogorov-Smirnov Z test).particularly the shorter C-terminal isoform, might be
involved in the regulation of head size. Given that we
have shown recently how head-size evaluations in zebra-
fish embryos can serve as a surrogate for the evaluation
of candidate genes for neurocognitive traits,21 we decided
to create a zebrafish morphant for auts2. Using reciprocal
BLAST, we identified a single Danio rerio AUTS2 ortholog
(auts2 on chromosome 10; 62% amino acid identity and
72% similarity with the long isoform of AUTS2)
(Figure 4A). We were able to detect endogenous auts2
message by RT-PCR as early as embryonic 5-somite stage
by using both 50 and 30 primer sets (data not shown).
Next, we designed two splice-blocking morpholinos (sb-
MOs): a 50 MO targeting the splice donor site of exon 2
and a 30 MO targeting the splice donor site of exon 10
(the 50 and 30 MOs were chosen to suppress the full-length
transcript only and both auts2 transcripts [if present],
respectively; see Figure 4A and Figure S5). RT experiments
demonstrated that both sb-MOs affected correct splicing
of the auts2 transcript (Figure S5). Masked scoring of
embryos at 3 dpf showed a reproducible microcephaly
phenotype—53% and 48% for 50 and 30 sb-MOs, respec-
tively (Figures 5A and 5B)—that was concomitant with
the efficiency of splice blocking of the two sb-MOs, as es-
tablished by RT-PCR (Figure S5). The phenotype was216 The American Journal of Human Genetics 92, 210–220, Februaryunlikely to be driven by overall developmental delay;
morphants had a normal appearance with regard to their
pigment cells, there was no apparent pathology in other
internal organs, such as the heart or the swim bladder,
and their body length was indistinguishable from that
of control embryos from the same clutch (Figure 5C).
The phenotype was specific; the observed microcephaly
caused by the two sb-MOs could be rescued efficiently
with coinjection of wild-type human full-length mRNA
(GenBank JQ670866) (Figures 5A and 5B). Strikingly,
microcephalic embryos could also be rescued with the
human short AUTS2 isoform (GenBank JQ670867) in
a manner indistinguishable from that with the full-length
form, indicating that the observed phenotype is driven by
sequences in exons 9–19. We also observed another recur-
rent dysmorphic feature in knockdown zebrafish mor-
phants: micrognathia and retrognathia. To quantify this
defect, we stained embryos injected with either a 50 or 30
sb-MO at 5 dpf with Alcian blue and performed quantita-
tive morphometric analysis of the lower jaw. We observed
a significant reduction of the distance between the Meckel
and ceratohyal cartilages, indicating a reduced lower-jaw
size comparable to the micrognathia and retrognathia
seen in individuals with an AUTS2 disruption (Figures
5D and 5E).
To probe the underlying cause(s) of the microcephalic
phenotype further, we stained embryos at 2 dpf with anti-
bodies against phosphohistone H3, an M phase marker,
and HuC/D, a marker of postmitotic neurons.22 This time
point was selected because it precedes the development
of microcephaly and, as such, allowed us to evaluate the
forebrain prior to gross anatomical defects. We observed
a striking reduction in phosphohistone-H3- and HuC/D-
positive cells in embryos injected with either the 50 or
the 30 MO, as well as loss of bilateral symmetry in HuC/D
protein levels, indicating that the microcephaly pheno-
type is caused by disturbed neuronal proliferation. Both
phenotypes could be rescued with the 30 human mRNA
(Figure 6).Discussion
Our studies of 49,684 individuals with ID and/or MCAs re-
vealed deletions in AUTS2 in 44 individuals; at least 24 of
these deletions involved exons. In contrast, we only found
nine AUTS2 deletions, none of which were exonic, in
16,784 controls, strongly indicating that intragenic
AUTS2 deletions that disrupt at least a portion of the
coding sequence are a recurrent cause of neurodevelop-
mental defects in humans. The frequency of exonic dele-
tions that we found was 1 in 2,000 cases, comparable
with some of the recurrent deletions described by Cooper
et al.,12 such as the 10q23 deletion (NRG3 [MIM 605533]
and GRID1 [MIM 610659]) and deletions causing Sotos
syndrome (MIM 117550) or Rubinstein-Taybi syndrome
(MIM 180849). This observed frequency is likely to be an7, 2013
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Figure 4. Exon Organization of AUTS2
and Its Zebrafish Ortholog and Identifica-
tion of a Novel Transcriptional Start Site in
Exon 9 of Full-Length Human AUTS2
(A) Exon organization of AUTS2 orthologs
in humans and zebrafish. Arrows indicate
two TSSs used in human brain mRNA.
The alternative novel TSS is located 1.17
Mb downstream of the standard TSS
in the cluster containing exons 7–19.
Exons 1–6 (zebrafish) represent conserved
sequences that are not annotated in the
current zebrafish genome (for details, see
Figure S4).
(B) Identification of an alternative AUTS2
transcript detected in human brain
mRNA by 50 RACE. The alternative tran-
script starts in the center of exon 9
(asterisk) and contains the indicated
cDNA sequence (in italics). The mRNA
was spliced to exon 10 with the second of
two known splice donor sites in exon 9,
resulting in the incorporation of seven
alternatively spliced amino acids (rectangle). The alternativemRNA uses the same reading frame as the conventional transcript. Conven-
tional exons are in uppercase, and introns are in lowercase. See also Figures S1 and S3.underestimate because smaller deletions (single-exon dele-
tions and small indels within exons) and nonsense muta-
tions are likely to cause AUTS2 syndrome and are missed
with the techniques used here.
The individuals (cases 1–17) with an AUTS2 aberration
affecting the coding sequence studied here, together with
previously reported cases, allowed us to delineate recurrent
phenotypic features (ID, autism, microcephaly, mild short
stature, feeding difficulties, hypotonia, cerebral palsy, and
dysmorphic features) of the AUTS2 syndrome. Only 1 (the
father of case 1) of the 21 persons studied in detail did not
have any features of the AUTS2 syndrome, indicating
a penetrance of around 95%. Although the phenotype of
the AUTS2 syndrome is variable and the features are some-
times subtle, there are other examples where reverse geno-
mics have shown variable phenotypes associated with the
same locus.23,24 Several lines of evidence support the
causality of AUTS2 deletions for this broad phenotypic
spectrum; these are (1) the significant enrichment of
exonic deletions in cases, (2) the fact that auts2 zebrafish
morphants show microcephaly and smaller lower-jaw
size comparable to the human phenotype (these aberrant
phenotypes can be fully rescued by both full-length and
short 30 human AUTS2 transcript), (3) the fact that no indi-
viduals with an exonic deletion had a second rare de novo
CNV, and (4) the fact that all exonic deletions were de novo
or inherited from an affected parent except for the in-
frame exon 2 deletion of case 1.
Individuals with in-frame exonic deletions in the 50
part of the gene (exons 1–5) showed a milder phenotype
mainly restricted to neurocognitive defects with no or
limited dysmorphology or were normal, like the father
of case 1. In contrast, deletions of the C-terminal part, en-
coded by both the short and full-length transcripts, cause
a more severe phenotype including dysmorphology. ThisThe Americcould potentially be related to the gene structure: because
exons 7–19 are closely packed, deletions in this part of the
gene often result in larger disruptions of the coding
sequence. However, we also observed severe phenotypes
in cases with small in-frame 30 deletions, as well as in 30
MO zebrafish, where the shorter 30 transcript was suffi-
cient to rescue the dysmorphology (microcephaly and
smaller jaw size). This might suggest that the C-terminal
part of the protein contains the crucial region for the
observed dysmorphology. It is uncertain whether the
shorter 30 transcript is expressed at sufficiently high levels
to explain the milder phenotype in humans with in-
frame 50 deletions. The milder phenotype might well be
explained by the fact that AUTS2 alleles with these dele-
tions can still be transcribed and can thus result in
a protein that contains the important C-terminal
sequences.
In aggregate, our data indicate that AUTS2 deletions,
particularly when they involve the C terminus, give rise
to a highly penetrant syndrome that includes neurocogni-
tive defects. Our data highlight transcriptional complexity
at the AUTS2 locus and show that careful genomic,
genetic, and functional dissection of such complexity
can offer both clinical and mechanistic insights. Although
little is known about the function(s) of AUTS2 or its iso-
forms, a role in neurodevelopment is suggested by the
reduction of postmitotic neurons and loss of bilateral
symmetry, which both might be driven by neurogenesis
and/or migration defects in the zebrafish auts2 mor-
phants. The zebrafish model can be of great value for
further studies of AUTS2 function and can be helpful for
defining the pathogenicity of specific genomic disrup-
tions.
In conclusion, detailed analysis of the AUTS2 locus al-
lowed us to delineate a hitherto undescribedmicrodeletionan Journal of Human Genetics 92, 210–220, February 7, 2013 217
Figure 5. Suppression of auts2 in Zebrafish Leads to Small Head Size and Craniofacial Defects
(A) Lateral views of representative control embryos and embryos injected with auts2 MOs.
(B) Quantification of microcephaly was performed in embryo batches injected with 4.5 ng 50 MO (targeting exon 2 donor splice) or 6 ng
30 MO (targeting exon 10 donor splice) plus 100 pg wild-type human AUTS2 full-length (FL) or short isoform (30) mRNAs (n ¼ 56–91
embryos per injection). p values are denoted on the bar graph. The following abbreviation is used: NS, nonsignificant.
(C) No significant difference in body length was observed in auts2morphants and rescued embryos at 2 dpf. Bars represent the average
length of 30 embryos, which were scored blindly to injection cocktail. Data are shown as the mean 5 SD.
(D) Ventral views of representative control embryos and those injected with auts2MOs (either a 30 or 50 MO) at 5 dpf. Cartilage structures
were visualized by whole-mount Alcian-blue staining at 5 dpf, allowing measurement of the distance between ceratohyal and Meckel’s
cartilages (red lines).
(E) Averaged distance measurements are presented as the mean5 SEM. The corresponding p values are denoted on the bar graph (two-
tailed t test comparisons). The following abbreviations are used: ch, ceratohyal cartilage; and Mk, Meckel’s cartilage.syndrome occurring with a frequency that approximates
the frequency of deletions causing Sotos syndrome or Ru-
binstein-Taby syndrome.12 This AUTS2 syndrome has
presumably remained undescribed because (1) the specific218 The American Journal of Human Genetics 92, 210–220, Februarycharacteristics of the resulting phenotype are subtle,
(2) the severity of the syndrome is highly variable, and
(3) the penetrance is dependent on location and type of
deletion.7, 2013
Figure 6. Suppression of auts2 Leads to Reduced HuC/D Protein Levels and Fewer Proliferating Cells
(A) Suppressionofauts2 leads to adecreaseofHuC/D levels at 2dpf.Representativephotographs (withHuC/D-antibody staining) showthe
ventral views of a control, an embryo injected with an auts2MO, and a rescued embryo injected with an auts2MOplus 30 human AUTS2
mRNA at 2 dpf. HuC/D levels in the anterior forebrain of the embryo injected with the auts2MOare considerably lower than those of the
control embryo. This defect was rescued significantly by coinjection of full-length (FL) or short isoform (30) human AUTS2mRNAs.
(B) Percentage of embryos with normal, bilateral HuC/D protein levels in the anterior forebrain (blue) or decreased and/or unilateral
HuC/D protein levels (red) in embryo batches injected with auts2 MOs alone or MOs plus human AUTS2 FL or 30 mRNA (MO þ 30
mRNA). p values are denoted on the bar graph.
(C) Phosphohistone-H3 staining for proliferating cells in the zebrafish brain at 2 dpf.
(D) Quantification of phosphohistone-H3-staining intensities from 20 embryos each (control embryos or embryos injected with MOs
alone or MOs plus 30 or 50 human AUTS2 mRNA). Data are represented as the mean 5 SEM. The corresponding p values are denoted
on the bar graph (two-tailed t test comparisons between MO-injected and rescued embryos).Supplemental Data
Supplemental Data include five figures and seven tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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